Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: Robert Voigt who wrote (468)	12/19/1997 6:20:00 PM
From: jim black	Read Replies (1) \| Respond to of 965

To all: I saw the list of side effects and must say that if the report was true I'd have a hard time getting all that worried. I am a physician who treats serious illness and I cannot see a pattern to the side effects. Good luck to all, and btw am long as of yesterday.

To: Robert Voigt who wrote (468)	12/20/1997 8:25:00 AM
From: Wilfredo Pagani	Respond to of 965

Anti tnf antibodies now called avakine was associated to the diagnosis of lymphoma in a higher % than expected (both the patient with Rheumathoid arthritis and Crohns disease had risk for lymphoma specially if previously tx with immunosuppresant agent ) Nevertheles the evidence shows a dramatic improvement in the activity index and healing of the Crohn's patient with fistula that the IBD patient and organitation are pushing for its release. WPD

To: Robert Voigt who wrote (468)	12/21/1997 11:49:00 AM
From: PawPr	Respond to of 965

This just shows how little Cramer knows. During any clinical trial, the FDA must be warned of "serious side effects" IMMEDIATELY, and they will stop the trial if they feel such action is warranted.

To: Robert Voigt who wrote (468)	12/21/1997 9:44:00 PM
From: FNS	Read Replies (1) \| Respond to of 965

Robert: James Cramer is a sorta cocky guy who likes to entertain at times, IMHO...even I like to hear the guy 'pitch', but one should take what he says as not based on pure journalism but on salesmanship. Sorry, I don't mean to offend anyone with my stereotype of him, but that's the way I see it! However, he is a guy I would like to have in my corner rather than be against me. In any event, should Avakine get accelerated approval, he will probably say, "See! I told you so!". I would rather believe in CEO Holveck, at this point. Much ground has been paved -- and fundamentals still sound. FNS